MacroGenics, Inc. (NASDAQ:MGNX) will be announcing its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. During the same period in the previous year, the business earned $1.12 earnings per share. MacroGenics’s revenue was down 97.9% on a year-over-year basis. On average, analysts expect MacroGenics to post $-4.24 EPS for the current fiscal year and $-4.03 EPS for the next fiscal year.

TRADEMARK VIOLATION NOTICE: “MacroGenics, Inc. (MGNX) to Release Quarterly Earnings on Wednesday” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/02/macrogenics-inc-mgnx-to-release-quarterly-earnings-on-wednesday.html.

Several research analysts recently weighed in on MGNX shares. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BidaskClub downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. Finally, Morgan Stanley dropped their target price on shares of MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. MacroGenics currently has a consensus rating of “Hold” and an average price target of $30.30.

In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares in the company, valued at approximately $800,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.30% of the stock is owned by insiders.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.